Candel Therapeutics Inc (NASDAQ: CADL) on Tuesday, soared 3.40% from the previous trading day, before settling in for the closing price of $6.48. Within the past 52 weeks, CADL’s price has moved between $1.16 and $14.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -25.00%. The company achieved an average annual earnings per share of -21.37%. With a float of $32.34 million, this company’s outstanding shares have now reached $44.48 million.
Let’s determine the extent of company efficiency that accounts for 42 employees. In terms of profitability, gross margin is 54.28%, operating margin of -2001.58%, and the pretax margin is -2939.13%.
Candel Therapeutics Inc (CADL) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Candel Therapeutics Inc is 27.29%, while institutional ownership is 16.18%. The most recent insider transaction that took place on Jan 15 ’25, was worth 97,783. In this transaction Chief Scientific Officer of this company sold 13,534 shares at a rate of $7.22, taking the stock ownership to the 110,673 shares. Before that another transaction happened on Jan 15 ’25, when Company’s Chief Technology Officer sold 14,322 for $7.22, making the entire transaction worth $103,476. This insider now owns 96,790 shares in total.
Candel Therapeutics Inc (CADL) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -21.37% per share during the next fiscal year.
Candel Therapeutics Inc (NASDAQ: CADL) Trading Performance Indicators
Candel Therapeutics Inc (CADL) is currently performing well based on its current performance indicators. A quick ratio of 1.18 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.74, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -1.35 in one year’s time.
Technical Analysis of Candel Therapeutics Inc (CADL)
Looking closely at Candel Therapeutics Inc (NASDAQ: CADL), its last 5-days average volume was 0.78 million, which is a drop from its year-to-date volume of 1.38 million. As of the previous 9 days, the stock’s Stochastic %D was 15.68%. Additionally, its Average True Range was 0.86.
During the past 100 days, Candel Therapeutics Inc’s (CADL) raw stochastic average was set at 26.95%, which indicates a significant increase from 15.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.58% in the past 14 days, which was lower than the 150.11% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.62, while its 200-day Moving Average is $6.72. However, in the short run, Candel Therapeutics Inc’s stock first resistance to watch stands at $6.94. Second resistance stands at $7.17. The third major resistance level sits at $7.49. If the price goes on to break the first support level at $6.39, it is likely to go to the next support level at $6.07. Should the price break the second support level, the third support level stands at $5.84.
Candel Therapeutics Inc (NASDAQ: CADL) Key Stats
Market capitalization of the company is 297.99 million based on 32,476K outstanding shares. Right now, sales total 0 K and income totals -37,940 K. The company made 0 K in profit during its latest quarter, and -10,650 K in sales during its previous quarter.
